Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT02204215
Other study ID # EA-ICUAW
Secondary ID
Status Enrolling by invitation
Phase N/A
First received July 25, 2014
Last updated July 28, 2014
Start date January 2014
Est. completion date December 2015

Study information

Verified date July 2014
Source Jiangsu Province Hospital of Traditional Chinese Medicine
Contact n/a
Is FDA regulated No
Health authority China: State Administration of Traditional Chinese Medicine
Study type Interventional

Clinical Trial Summary

Intensive care unit acquired weakness (ICU-AW) is common and dramatically affect recovery. The purpose of this study is to determine whether electric acupuncture therapy is effective in the treatment of ICU-AW especially in the patients receiving mechanical ventilation with sepsis or multiorgan system failure.


Description:

The principle of acupuncture is to produce bioelectric current, as a consequence, to invigorate the circulation, promote tissue regeneration, relieve pain, enhance the immune function, etc. And electric acupuncture can stimulate bioelectricity activities at acupoints, out of reach for ordinary acupuncture effect, especially in the fields of nerve/muscle recovery and regeneration.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 40
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of sepsis or multiple organ dysfunction syndrome

- Within 48 hours from the initiation of mechanical ventilation

Exclusion Criteria:

- Pregnant patients

- Neuromuscular disease or cerebrovascular accident

- With temporary or permanent pacemaker

- Need to use neuromuscular blocking agents

- Inactivity for more than 5 days before ICU admission

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
electric acupuncture
Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
Other:
conservative
General treatment, without electric acupuncture, include passive range-of-motion exercise,q2H turning,minimizing the use of sedation, etc.

Locations

Country Name City State
China Department of Intensive Care Unit, Jiangsu Province Hospital of TCM Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Province Hospital of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary strength related parameters muscle force, arm circumference, skin fold thickness Participants will be followed until the date of weaning from mechanical ventilation, an expected average of 8 weeks No
Secondary mechanical ventilation duration the time span from the beginning of mechanical ventilation, till the weaning of mechanical ventilation Participants will be followed until the date of weaning from mechanical ventilation, an expected average of 8 weeks No
Secondary 28-day mortality the mortality till the 28th day after mechanical ventilation Participants will be followed until the 28th day after mechanical ventilation No
Secondary number of participants with adverse events of electric acupuncture the adverse enents include fainting, infection, bleeding, viscera damage, and so on. Participants will be followed until the date of weaning from mechanical ventilation, an expected average of 8 weeks Yes
Secondary ICU duration the time span from the beginning of mechanical ventilation, till the date of discharge from the ICU Participants will be followed until the date of discharge from the ICU, an expected average of 8 weeks No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3